iHuman (IH)
NYSE:IH
Top Page
iHuman
(NYSE:IH)
Select Model
Select Model
Rating:67Neutral
Price Target:
$2.00
▲(0.00% Upside)
Action:ReiteratedDate:01/06/26
Score is driven primarily by stable financial positioning (low leverage and solid operating margins) but offset by declining revenue, weaker net profitability, and a sharp free-cash-flow drop. Valuation is supportive (low P/E and strong yield), while technical indicators are notably bearish and pull the score down.
Positive Factors
Low leverage / strong balance sheet
Extremely low leverage and a high equity ratio provide lasting financial flexibility. This reduces interest burden and preserves capacity to fund R&D, content investment, partnerships or M&A during downturns, supporting durable operations and strategic optionality over months.
Negative Factors
Declining revenue
A near-double-digit topline decline signals weakening demand or monetization, which undermines scale economics. Persistent revenue contraction reduces ability to absorb fixed costs, threatens long-term growth trajectory, and limits scope for sustainable margin recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Extremely low leverage and a high equity ratio provide lasting financial flexibility. This reduces interest burden and preserves capacity to fund R&D, content investment, partnerships or M&A during downturns, supporting durable operations and strategic optionality over months.
Read all positive factors
iHuman (IH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$89.81M
Dividend Yield3.93%
Average Volume (3M)17.50K
Price to Earnings (P/E)2.5
Beta (1Y)0.38
Revenue Growth-8.09%
EPS Growth-15.28%
CountryUS
Employees723
SectorConsumer Defensive
Sector Strength42
IndustryEducation & Training Services
Share Statistics
EPS (TTM)0.04
Shares Outstanding22,544,950
10 Day Avg. Volume15,971
30 Day Avg. Volume17,505
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.13
Price to Sales (P/S)0.14
P/FCF Ratio2.53
Enterprise Value/Market Cap-11.37
Enterprise Value/Revenue-1.16
Enterprise Value/Gross Profit-1.70
Enterprise Value/Ebitda-13.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iHuman Business Overview & Revenue Model
Company Description
iHuman Inc. provides intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman ABC, iH...
How the Company Makes Money
iHuman generates revenue through a subscription-based model, where users pay for access to its suite of educational apps and content. This recurring revenue stream is complemented by in-app purchases for additional features, content, and enhanceme...
iHuman Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
75
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 882.69M | 922.20M | 1.02B | 985.52M | 944.72M | 531.91M |
| Gross Profit | 599.83M | 640.15M | 721.27M | 691.17M | 660.62M | 365.44M |
| EBITDA | 76.70M | 85.57M | 171.58M | 122.41M | -47.83M | -41.64M |
| Net Income | 110.03M | 98.59M | 180.91M | 109.82M | -37.05M | -37.48M |
Balance Sheet | ||||||
| Total Assets | 1.34B | 1.42B | 1.45B | 1.33B | 1.10B | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 1.10B | 1.17B | 1.21B | 1.05B | 855.36M | 861.68M |
| Total Debt | 12.28M | 14.91M | 3.86M | 9.02M | 34.25M | 6.61M |
| Total Liabilities | 365.70M | 458.80M | 492.69M | 563.95M | 492.51M | 404.29M |
| Stockholders Equity | 969.39M | 960.85M | 957.80M | 769.45M | 608.37M | 642.65M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 51.10M | 165.61M | 1.25B | 5.93M | 207.08M |
| Operating Cash Flow | 0.00 | 58.55M | 172.12M | 1.29B | 38.21M | 222.99M |
| Investing Cash Flow | 0.00 | -52.76M | -6.51M | -225.03M | -31.95M | -15.91M |
| Financing Cash Flow | 0.00 | -102.28M | -9.45M | -47.66M | 410.00K | 571.96M |
iHuman Technical Analysis
Neutral
2.00
Price Trends
1.81
Negative
2.05
Negative
2.41
Negative
Market Momentum
-0.04
Negative
49.93
Neutral
63.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IH, the sentiment is Neutral. The current price of 2 is above the 20-day moving average (MA) of 1.75, above the 50-day MA of 1.81, and below the 200-day MA of 2.41, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 49.93 is Neutral, neither overbought nor oversold. The STOCH value of 63.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IH.
iHuman Risk Analysis
iHuman disclosed 87 risk factors in its most recent earnings report. iHuman reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
iHuman Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $47.81M | 1.57 | 51.85% | ― | -0.84% | -11.01% | |
67 Neutral | $89.81M | 2.45 | 11.71% | 3.93% | -8.09% | -15.28% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
45 Neutral | $34.19M | -0.56 | -709.20% | ― | -3.55% | 61.83% | |
44 Neutral | $125.10M | -0.19 | 69.84% | ― | 92.26% | -1.18% | |
44 Neutral | $32.64M | -1.05 | -37.31% | ― | -64.39% | -305.82% | |
42 Neutral | $4.06M | ― | -19.03% | ― | ― | ― |
* Consumer Defensive Sector Average
IH
iHuman
1.76
0.02
1.15%
COE
China Online Education Group
21.50
5.62
35.39%
STG
Sunlands Online Education Group
3.51
-1.28
-26.72%
SKIL
Skillsoft
4.22
-14.14
-77.02%
KIDZ
Classover Holdings
2.52
-91.90
-97.33%
GNS
Genius Group Limited
0.38
0.11
44.23%
iHuman Corporate Events
iHuman Posts Lower Q3 2025 Revenue but Extends Profit Streak and Expands AI Learning Ecosystem
Dec 29, 2025
On December 29, 2025, iHuman Inc. reported unaudited financial results for the third quarter ended September 30, 2025, showing that revenues declined to RMB205.8 million from RMB239.4 million a year earlier, with gross profit, operating income and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.